UNASSIGNED: Background   The most common site of @entity3 for soft @entity242 (STSs) is the lung. In @entity1 who are candidates for resection, metastasectomy improves survival. Debate remains, however, on approach and @entity1 selection for surgery. Methods   We retrospectively analyzed demographics, @entity5 characteristics, peri- and postoperative factors for 53 @entity1 who underwent lung metastasectomy for @entity2031 from 1989 to 2013. Disease-free intervals (DFIs) and survival were determined. Kaplan-Meier estimates and log-rank test were used for comparison and survival analyses. Results   Median overall survival (diagnosis to @entity204 or last visit) was 59.9 months (IQR: 118.5), with mean follow-up of 85.3 months (SD: 69.5). Post-lung metastasectomy survival was 82.9%, 52.2%, 28.3%, and 13.3% at 1, 3, 5, and 10 years, respectively. Age at diagnosis of less than 50 years (p   =   0.037), a low pathologic grade (p   =   0.040), and a DFI until @entity3 of greater than 13.5 months (p   =   0.007) were significant predictors of improved survival. Conclusion   @entity1 diagnosed at a younger age with low-grade @entity5 and those with a longer DFI prior to @entity3 diagnosis gain the greatest survival advantage with surgery.

Survival Following Lung Metastasectomy in Soft Tissue XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity242 :: ('MESH:D012509', 'Disease') :: ['tissue sarcomas'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity2031 :: ('412', 'Gene') :: ['STS'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity242 :: (MESH:D012509,Disease) :: ['Sarcomas']
